Emily Menendez

Emily Menendez is an assistant editor for GU Oncology Now and Cancer Nursing Today. She uses her copywriting experience to contribute content on the latest updates in the oncology nursing sphere. Ms. Menendez received her BA from the University of Central Florida.

Articles by Emily Menendez

Emily MenendezUpper Tract Urothelial Carcinoma | May 21, 2024
The use of minimally invasive RNU is linked to improved median OS and 90-day mortality in octogenarian patients with UTUC.
Read More
Emily MenendezAdvanced Urothelial Carcinoma | May 20, 2024
Previous studies have demonstrated the efficacy of postchemotherapy nivolumab with high-dose ipilimumab for metastatic UC.
Emily MenendezRenal Cell Carcinoma Diagnostics | May 15, 2024
Kidney injury molecule-1 is a transmembrane protein that can serve as a urinary indicator of acute renal tubular injury.
Emily MenendezLocalized | May 10, 2024
Prostate cancer is the 2nd most diagnosed cancer among men worldwide, but the disease lacks established re-treatment options.
Emily MenendezAdvanced Urothelial Carcinoma | May 8, 2024
Data on the type of treatment received in each line of therapy, as well as the attrition rates, were recorded.
Emily MenendezCRPC | May 7, 2024
Previous research has shown that the effects of androgen and PSMA receptors can complement each other if used concurrently.
Emily MenendezRenal Cell Carcinoma | May 5, 2024
Approximately 82,000 new cases of RCC are diagnosed each year in the US, but effective early detection methods are lacking.
Emily MenendezMuscle Invasive Urothelial Carcinoma | May 5, 2024
New findings from the Nure-Combo trial examined the use of ABX with nivolumab followed by RC and adjuvant nivolumab.
Emily MenendezUrothelial Carcinoma | May 3, 2024
Researchers compared open cystectomy with a robotic approach to determine differences between the 2 procedures.
Emily MenendezAdvanced Renal Cell Carcinoma | May 3, 2024
Researchers completed a comprehensive evaluation of features that can serve as biomarkers of response to ICB therapy in mRCC.
Emily MenendezProstate Cancer | May 3, 2024
The study group received 6-month neoadjuvant LHRH-α plus abitrexone with prednisone.
Emily MenendezNon-Muscle Invasive Urothelial Carcinoma | May 3, 2024
Intravesical EMDA/MMC can serve as a safe and effective option for patients with high-risk NMIBC who fail BCG therapy.
Emily MenendezUrothelial Carcinoma | May 3, 2024
Researchers sought to determine if ctDNA detection before cystectomy is linked to poor outcomes and lymph node involvement.
Emily MenendezUrothelial Carcinoma | May 3, 2024
Dr. Powles is recognized for his research efforts in bladder cancer that have spanned over two decades, including EV-302.
Emily MenendezmCSPC | May 1, 2024
An analysis of the phase 3 ARASENS study revealed new information on PSA responses and their association with outcomes.
Emily MenendezRenal Cell Carcinoma | April 30, 2024
A review analyzed 30 meta-analyses to determine the association between pretreatment NLR and immunotherapy outcomes.
Emily MenendezRenal Cell Carcinoma Diagnostics | April 30, 2024
A new study by an international research team has identified new susceptibility regions associated with RCC development risk.
Emily MenendezProstate Cancer Diagnostics | April 24, 2024
The benefits of PSA screening alone are offset by excess negative biopsies and the over-detection of low-grade cancers.
Emily MenendezTesticular, Penile, and Rare Malignancies | April 19, 2024
The IGCCCG was used to compare the survival probabilities of patients with testicular GCTs with or without teratoma.
Emily MenendeznccRCC | April 17, 2024
The ARON-1 study investigated the efficacy of 1L treatment with TKIs versus IO-based combinations in patients with pRCC.